United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived
February 26, 2013 1:10 PM ESTBrean Capital downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold.
"We are downgrading United to Hold from Buy due to the achievement of our target price and our view that the next catalyst, a second FDA action on a refiled oral... More
